mProX™ Human CD200 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD200 has been studied in various applications. In the field of Alzheimer's disease (AD), CD200 has been explored in relation to the effects of angiotensin-converting enzyme inhibitors (ACEI) and statins therapies on AD-related neuropathology. The study found that treatment with ACEI and statins resulted in changes in the expression of CD200, among other proteins and genes, in both human patients and transgenic mice. CD200 was also found to be significantly affected by treatments in multiple myeloma (MM) patients, where its expression patterns were correlated with molecular genetic prognostic parameters. Additionally, CD200 has been investigated in the context of immune checkpoint disorders and Epstein-Barr virus (EBV) reactivation in immunodeficient patients with hematological malignancies. The study found that CD200 expression was altered in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and hairy cell leukemia (HCL), suggesting a potential interplay between immune checkpoint dysregulation and EBV reactivation. Furthermore, CD200 has been evaluated as a marker for the differential diagnosis of B-cell lymphoproliferative disorders (B-LPDs). The study found that CD200 expression could differentiate CLL from MCL, and HCL consistently expressed CD200. Lastly, CD200 has been studied in relation to neuroinflammation and amyloid-β deposition in AD. Integrating transcriptomics and TSPO PET imaging, the study revealed that CD200 played a role in regulating neuroinflammation, Aβ deposition, and cognitive dysfunction in AD patients. These findings highlight the potential applications of CD200 in various aspects of AD, MM, B-LPDs, and immunodeficiency-related hematological malignancies.